NOXXON Pharma AG has appointed Lawrence E. Posner, a senior pharmaceutical executive, to its board of directors. Dr Posner has more than 25 years of experience in pharmaceutical research and development including executive positions with Yamanouchi Pharma America, Bayer and Lederle Laboratories. A graduate of Brandeis University in the US, Dr Posner earned his MD at Case Western Reserve University and later specialised in medical oncology and tumour virology while working at the National Cancer Institute in Washington DC.
Based in Berlin, Germany, NOXXON develops aptamers using mirror-image nucleic acids which it calls Spiegelmers. It is investigating these for a number of therapeutic areas.
Source
NOXXON press release, 8 July 2008
Copyright 2008 Evernow Publishing Ltd